Top-News
  • Depot
  • Watchlist
  • Glocke

  • Innovent Biologics Inc.

    49,7095 $ +3,2795 $ +7,06%
    In : 42,692 € | 10.09.25 19:16:10 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    ISIN: US45783L1017
    US-Symbol: IVBIY
    • Push
    • Intraday
    • 5 Tage
    • 3 Monate
    • 1 Jahr
    • Gesamt
    Innovent Biologics Inc. Chart

    Performance

    Keine Daten verfügbar

    Nachrichten

    Zeit Titel Quelle
    19.09.25 Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes PR Newswire
    18.09.25 Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) PR Newswire
    15.09.25 Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 PR Newswire
    07.09.25 Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-​Pacific League of Associations for Rheumatology Congress PR Newswire
    27.08.25 Innovent Announces 2025 Interim Results and Business Updates PR Newswire
    24.08.25 Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer PR Newswire
    Werbung

    Mehr Nachrichten kostenlos abonnieren

    E-Mail-Adresse
    Benachrichtigungen von ARIVA.DE
    (Mit der Bestellung akzeptierst du die Datenschutzhinweise)

    Analysen

    • 12 Monate
    • 6 Monate
    • 3 Monate
    • 1 Monat
    Kaufen Halten Verkaufen
    Analysten 0 0 0
    Markt-Lotsen 0 0 0